The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 ...

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...

Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation ...

Novo Nordisk A/S and Eli Lilly & Co. shares fell after President Donald Trump said the price of the blockbuster diabetes drug ...

During a press conference, Trump specifically mentioned Ozempic, referring to it as "the fat loss drug" when asked about a $1 ...

The new guidelines are yet another sign that GLP-1 drugs like Ozempic are likely to continue soaring in popularity as a ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends AstraZeneca Plc and Novo ...

President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and ...

Doctors called it “huge for patients,” if true. Patients who’ve struggled to afford the pricey medicines shared hope the ...